SESSION OF 2024
SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2596
As Recommended by House Committee on
Health and Human Services
Brief*
HB 2596 would amend the state Uniform Controlled
Substances Act (Act). The bill would also make technical
changes.
[Note: The federal and state controlled substances acts
provide for a five-schedule classification system of
substances. These classifications are based on a substance’s
accepted medical use, the potential for abuse or addiction,
and harmfulness. Schedule I contains the substances with
the most potential for abuse, harm, and no recognized
medical uses, while Schedule V provides the least dangerous
substances with known medical uses.]
Schedule I (Section 2)
The bill would add 35 new substances to the Act
including 23 fentanyl-related controlled substances.
Schedule II (Section 3)
The bill would add four additional substances to be
excluded from control as Schedule II opioids: thebaine-
derived butorphanol, naldemedine, naloxegol, and
samidorphen.
____________________
*Supplemental notes are prepared by the Legislative Research
Department and do not express legislative intent. The supplemental
note and fiscal note for this bill may be accessed on the Internet at
http://www.kslegislature.org Schedule IV (Section 4)
The bill would add daridorexant (brand name Quiviviq),
a medication used to treat insomnia, and
serdexmethylphenidate, an active ingredient in medication
used to treat attention-deficit/hyperactivity disorder (ADHD) to
the list of Schedule IV substances. The bill would remove
fenfluramine (brand name Fintelpla), a U.S. Food and Drug
Administration (FDA)-approved medication used to treat
seizures, to mirror the federal descheduling of the drug.
Schedule V (Section 5)
The bill would add ganaxolone (brand name Ztalmy), a
medication used to treat a particular type of seizure, to
Schedule V.
Background
The bill was introduced in the House Committee on
Health and Human Services at the request of Representative
Clifford on behalf of the State Board of Pharmacy.
House Committee on Health and Human Services
In the House Committee hearing on January 29, 2024, a
representative of the State Board of Pharmacy (Board)
provided proponent testimony stating that the Board works
with the Kansas Bureau of Investigation (KBI) to review
changes made by the U.S. Drug Enforcement Administration
to the federal Controlled Substances Act. The bill would make
necessary changes to the state Uniform Controlled
Substances Act that reflect the federal updates.
Written-only proponent testimony was received from the
KBI.
2- 2596 A private citizen provided neutral testimony regarding
the inclusion of cannabis and marijuana-related drugs as
controlled substances.
No other testimony was provided.
Fiscal Information
According to the fiscal note prepared by the Division of
the Budget on the bill, the Board indicates that indicate
enactment of the bill would have no fiscal effect on the
agency. The Board noted that because pharmacies are
required to follow federal law as well as state law, any
changes that the Board would make because of enactment of
the bill would have no effect on the practice of pharmacy
because the stricter federal law has already been in place.
Uniform Controlled Substances Act; controlled substances; schedule; drugs;
substances; U.S. Drug Enforcement Administration; U.S. Federal Drug
Administration
3- 2596